YD Bio【YDES】銘柄情報

YD Bio Ltd (YDES) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

2.21

( -20.79% )

買値

2.20

売値

2.25

出来高

342,501

0.00 日の範囲 0.00

2.12 52 週間の範囲 25.00

時価総額

155.407M

前日終値

2.79

始値

時刻

2.2893

最終取引時間

20:00:00

財務取引量

VWAP

平均取引量 (3 か月)

US$ 22,372

発行済株式数

70,319,824

配当利回り

PER

-1.88

1 株当たり利益 (EPS)

-1.29

歳入

510.36k

純利益

-1.41M

YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan. YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.ydesgroup.com

本社

Taipei, Taiwan

設立

YD Bio Ltd is listed in the Healthcare sector of the ナスダック市場 with ticker YDES. The last closing price for YD Bio was US$2.79. Over the last year, YD Bio shares have traded in a share price range of US$ 2.12 to US$ 25.00.

YD Bio currently has 70,319,824 shares in issue. The market capitalisation of YD Bio is US$155.41 million. YD Bio has a price to earnings ratio (PE ratio) of -1.88.

YD Bio Limited Reports Full Year 2025 Financial Results

TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing...

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

Taipei, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES...

YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform

Taipei, Taiwan, Feb. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq:...

YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy

TAIWAN, Jan. 29, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a...

YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development

Taipei, Taiwan, Jan. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES...

YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap

Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES...

YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center

Taipei, Taiwan, Dec. 16, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES...

YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN

Taipei, Taiwan, Dec. 09, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES...

YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

Taipei, Taiwan, Dec. 02, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES...

YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics

Taipei, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.61	-21.6312056738	2.82	3.9003	2.12	119402	2.68703742	CS
4	-2.42	-52.2678185745	4.63	4.6999	2.12	38073	2.92358058	CS
12	-5.78	-72.3404255319	7.99	8	2.12	23158	4.13029454	CS
26	-9.81	-81.6139767055	12.02	13.105	2.12	30193	8.33198598	CS
52	-9.79	-81.5833333333	12	25	2.12	48628	12.53669056	CS
156	-8.29	-78.9523809524	10.5	31	2.12	32561	12.49593591	CS
260	-8.29	-78.9523809524	10.5	31	2.12	32561	12.49593591	CS